Receptos Stock Price, News & Analysis (NASDAQ:RCPT)

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Receptos (NASDAQ:RCPT)

Receptos logoReceptos, Inc. (Receptos) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics in immune disorders. Its product candidates span three disease areas. It is developing its lead asset, ozanimod (formerly RPC1063), as an oral therapy for the treatment of Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD), which consists of Ulcerative Colitis (UC) and Crohn's Disease (CD). It is developing its second asset, RPC4046, for the treatment of an allergic/immune-mediated disorder, Eosinophilic Esophagitis (EoE), for which it has been granted Orphan drug designation. Its research efforts include a preclinical program developing oral, small molecule, positive allosteric modulators (PAMs) of the glucagon-like peptide-1 receptor (GLP-1R) for the treatment of Type 2 Diabetes.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Bio Therapeutic Drugs
  • Symbol: NASDAQ:RCPT
  • CUSIP: N/A
  • Web: receptos.com
Profitability:
  • Trailing EPS: ($5.89)
  • Return on Equity: -44.89%
  • Return on Assets: -41.50%
 

Frequently Asked Questions for Receptos (NASDAQ:RCPT)

What is Receptos' stock symbol?

Receptos trades on the NASDAQ under the ticker symbol "RCPT."

How were Receptos' earnings last quarter?

Receptos Inc (NASDAQ:RCPT) posted its quarterly earnings data on Tuesday, May, 5th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($1.09) by $0.20. View Receptos' Earnings History.

Who are some of Receptos' key competitors?

How do I buy Receptos stock?

Shares of Receptos can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Receptos?

Receptos' mailing address is 3033 Science Park Road, Suite 300, SAN DIEGO, CA 92121, United States. The biopharmaceutical company can be reached via phone at +1-858-6525700.


MarketBeat Community Rating for Receptos (NASDAQ RCPT)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  135 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  205
MarketBeat's community ratings are surveys of what our community members think about Receptos and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Receptos (NASDAQ:RCPT)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for Receptos (NASDAQ:RCPT)

Price Target History for Receptos (NASDAQ:RCPT)

Analysts' Ratings History for Receptos (NASDAQ:RCPT)

Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History and Estimates Chart for Receptos (NASDAQ:RCPT)

Earnings by Quarter for Receptos (NASDAQ:RCPT)

Earnings History by Quarter for Receptos (NASDAQ RCPT)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/5/2015Q115($1.09)($1.29)$5.10 millionViewN/AView Earnings Details
3/3/2015Q414($1.19)($1.32)$2.06 millionViewN/AView Earnings Details
11/4/2014Q314($0.96)($1.19)$1.00 million$3.45 millionViewN/AView Earnings Details
8/12/2014Q214($0.85)($1.04)$1.28 million$1.10 millionViewN/AView Earnings Details
5/12/2014Q114($0.84)($1.01)$0.49 million$1.40 millionViewN/AView Earnings Details
3/5/2014($0.86)($0.86)$1.16 million$0.77 millionViewN/AView Earnings Details
10/30/2013Q313($0.61)($0.88)$1.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Receptos (NASDAQ:RCPT)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Receptos (NASDAQ:RCPT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Receptos (NASDAQ RCPT)

Insider Trades by Quarter for Receptos (NASDAQ:RCPT)

Insider Trades by Quarter for Receptos (NASDAQ RCPT)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/16/2015S. Edward TorresDirectorSell220,000$178.99$39,377,800.00View SEC Filing  
2/23/2015S. Edward TorresDirectorSell47,906$128.20$6,141,549.20View SEC Filing  
11/11/2014Faheem HasnainCEOSell200,000$109.47$21,894,000.00View SEC Filing  
11/11/2014Sheila GujrathiInsiderSell30,000$108.99$3,269,700.00View SEC Filing  
11/10/2014Chrysa MineoSVPSell30,000$109.73$3,291,900.00View SEC Filing  
11/10/2014Faheem HasnainCEOSell136,795$109.69$15,005,043.55View SEC Filing  
11/10/2014Marcus F BoehmCTOSell40,454$109.91$4,446,299.14View SEC Filing  
9/23/2014S. Edward TorresDirectorSell100,000$61.36$6,136,000.00View SEC Filing  
9/22/2014S. Edward TorresDirectorSell14,318$63.08$903,179.44View SEC Filing  
9/22/2014Sheila GujrathiInsiderSell30,000$61.45$1,843,500.00View SEC Filing  
9/19/2014S. Edward TorresDirectorSell169,570$62.55$10,606,603.50View SEC Filing  
9/18/2014S. Edward TorresDirectorSell91,513$62.77$5,744,271.01View SEC Filing  
9/17/2014David A HinkleCAOSell2,000$64.82$129,640.00View SEC Filing  
9/17/2014S. Edward TorresDirectorSell38,917$63.67$2,477,845.39View SEC Filing  
9/16/2014Graham K CooperCFOSell50,000$61.30$3,065,000.00View SEC Filing  
9/2/2014David A HinkleCAOSell2,000$52.80$105,600.00View SEC Filing  
8/13/2014David A HinkleCAOSell3,000$42.69$128,070.00View SEC Filing  
8/13/2014S. Edward TorresDirectorSell200,000$43.24$8,648,000.00View SEC Filing  
5/29/2014Kristina BurowDirectorSell153,698$29.74$4,570,978.52View SEC Filing  
5/21/2014S. Edward TorresDirectorSell424,068$25.26$10,711,957.68View SEC Filing  
5/15/2014S. Edward TorresDirectorSell90,075$27.37$2,465,352.75View SEC Filing  
5/14/2014Kristina BurowDirectorSell45,381$29.66$1,346,000.46View SEC Filing  
1/3/2014William RastetterDirectorSell37,359$30.85$1,152,525.15View SEC Filing  
1/2/2014William RastetterDirectorSell27,581$30.29$835,428.49View SEC Filing  
12/6/2013Amir NashatDirectorSell170,000$26.70$4,539,000.00View SEC Filing  
12/5/2013William RastetterDirectorSell500,000$27.63$13,815,000.00View SEC Filing  
11/18/2013Ventures Fund 2007 Flagshipmajor shareholderSell230,787$24.75$5,711,978.25View SEC Filing  
11/15/2013Amir NashatDirectorSell169,315$24.96$4,226,102.40View SEC Filing  
5/14/2013Amir NashatDirectorBuy151,343$14.00$2,118,802.00View SEC Filing  
5/14/2013Ventures Fund 2007 L FlagshipMajor ShareholderBuy107,142$14.00$1,499,988.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Receptos (NASDAQ:RCPT)

Latest Headlines for Receptos (NASDAQ RCPT)

Source:
DateHeadline
bluebird bio (BLUE) Names Mary Hedley to Board - StreetInsider.combluebird bio (BLUE) Names Mary Hedley to Board - StreetInsider.com
www.streetinsider.com - September 22 at 3:41 PM
bluebird bio Appoints Mary Lynne Hedley, Ph.D. to Board of Directors - Business Wire (press release)bluebird bio Appoints Mary Lynne Hedley, Ph.D. to Board of Directors - Business Wire (press release)
www.businesswire.com - September 20 at 8:17 AM
What Gilead Could Learn From Celgene - Seeking AlphaWhat Gilead Could Learn From Celgene - Seeking Alpha
seekingalpha.com - July 8 at 1:59 PM
Look Under The Hood: IWC Has 17% UpsideLook Under The Hood: IWC Has 17% Upside
www.thestreet.com - June 19 at 10:07 AM
Analysts Predict 20% Gains Ahead For IWCAnalysts Predict 20% Gains Ahead For IWC
www.thestreet.com - June 1 at 9:03 PM
3 Large-Cap Stocks for the Long Term3 Large-Cap Stocks for the Long Term
www.fool.com - May 30 at 7:10 PM
UPDATE 1-Celgenes multiple sclerosis drug succeeds in late-stage trialUPDATE 1-Celgene's multiple sclerosis drug succeeds in late-stage trial
www.businessinsider.com - May 23 at 9:40 AM
Celgene: Fears Over Revlimid Create A Buying OpportunityCelgene: Fears Over Revlimid Create A Buying Opportunity
seekingalpha.com - May 11 at 7:57 PM
The Implied Analyst 12-Month Target For IWCThe Implied Analyst 12-Month Target For IWC
www.thestreet.com - May 8 at 11:51 AM
Celgene Is A Must-Own StockCelgene Is A Must-Own Stock
seekingalpha.com - April 26 at 5:49 PM
Surprising Analyst 12-Month Target For IWCSurprising Analyst 12-Month Target For IWC
www.thestreet.com - April 12 at 6:35 PM
Multiple Abstracts Concerning MIS416 Mechanism of Action Accepted for Presentation at Upcoming American Academy of Neurologists MeetingMultiple Abstracts Concerning MIS416 Mechanism of Action Accepted for Presentation at Upcoming American Academy of Neurologists Meeting
au.finance.yahoo.com - March 7 at 7:20 PM
Insider Selling Picks Up as Market Volatility JumpsInsider Selling Picks Up as Market Volatility Jumps
247wallst.com - January 9 at 7:27 AM
Huge Biotech Trade Highlights Insider Selling as Market Hits Record HighsHuge Biotech Trade Highlights Insider Selling as Market Hits Record Highs
247wallst.com - January 9 at 7:27 AM
Celgene will buy drug developer Receptos for $7.32 billionCelgene will buy drug developer Receptos for $7.32 billion
www.latimes.com - January 9 at 7:27 AM
Is Celgene Transforming Itself With Mergers and Pacts?Is Celgene Transforming Itself With Mergers and Pacts?
247wallst.com - January 9 at 7:27 AM
Bioniz Therapeutics Appoints Paul Frohna M.D., Ph.D., Pharm. D., as Senior Vice President of Clinical DevelopmentBioniz Therapeutics Appoints Paul Frohna M.D., Ph.D., Pharm. D., as Senior Vice President of Clinical Development
www.prnewswire.com - December 20 at 7:10 PM
Is This a Potential $7 Billion Waste for Celgene Corporation?Is This a Potential $7 Billion Waste for Celgene Corporation?
www.fool.com - January 8 at 8:19 AM
RECEPTOS, INC. Files SEC form 10-Q, Quarterly ReportRECEPTOS, INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - July 30 at 6:12 AM

Social Media

Financials

Chart

Receptos (NASDAQ RCPT) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.